Valvular Heart Disease in Patients with Prolactinomas on Cabergoline Treatment

Dopamine agonists are the first line treatment of prolactinomas and Parkinson’s disease. Has shown an association between the use of high doses of ergot dopamine agonists, cabergoline and pergolide, and development of clinically significant (moderate to severe) heart valve regurgitation, valvular thickening and retraction in patients with Parkinson’s disease [1,2]. Because of this, he has appeared among endocrinologists concern about the safety of long term treatment with cabergoline in patients with hyperprolactinemia [3]. Most studies in these patients cabergoline hyperprolactinemic not show increased risk of Abstract